Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jun;143(6):2281-2284.e3.
doi: 10.1016/j.jaci.2019.01.026. Epub 2019 Feb 2.

Regulation of ectodomain shedding of ADAM33 in vitro and in vivo

Elizabeth R Davies  1 , Laura Denney  2 , Marieke Wandel  3 , Clare M Lloyd  2 , Donna E Davies  4 , Hans Michael Haitchi  4
Affiliations

Regulation of ectodomain shedding of ADAM33 in vitro and in vivo

Elizabeth R Davies et al. J Allergy Clin Immunol. 2019 Jun.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Regulation of ADAM33 shedding. Cos-7 cells expressing full-length catalytically active murine ADAM33 (A-F) or inactive ADAM33 E347A (Fig 1, A and B) were treated without or with TGF-β (5 ng/mL) for 8 hours and SMAD (SB431542) (Fig 1, C and D) or MAPK (PD98059) (Fig 1, E and F) inhibitors, as indicated. Soluble ADAM33 immunoreactivity and enzymatic activity in cell-free supernatants were assessed by Western blotting (inset) with densitometry (arbitrary units, AU) (Fig 1, A, C, and E) or in a fluorescence resonance energy transfer (FRET) peptide cleavage assay, respectively; in panel Fig 1, B, enzymatic activity in the supernatants is expressed as a percent of that measured in supernatants from untreated cells expressing full-length active ADAM33, whereas in panels D and F, activity is expressed as a percent of that measured in supernatants from TGF-β–treated cells. Data are expressed as mean + SD (n = 4 independent experiments). #P < .05, ##P < .01 vs control, *P < .05, **P < .01, ***P < .001.
Fig 2
Fig 2
Epithelial TGF-β enhances shedding of ADAM33 in vivo. Epithelial (Epi)Tgfb−/− or littermate Tgfb+/+ control mice were challenged with intranasal house dust mite (HDM) extract (A and B) or recombinant IL-33 (C and D) and, where indicated, recombinant TGF-β (Fig 2, C and D). Soluble ADAM33 immunoreactivity and enzyme activity in BALF were assessed by Western blotting (Fig 2, A and C) or FRET peptide cleavage assay, respectively; enzyme activity is expressed as relative fluorescent units per minute (RFU/min) (Fig 2, B and D). FRET, Fluorescence Resonance Energy Transfer. Data are mean + SD (n = 4-6 mice per group). Data are representative of 2 independent experiments. ##P < .01, ###P < .001 vs control, *P < .05, ***P < .001.
Fig E1
Fig E1
TGF-β enhances shedding of murine ADAM33. Cos-7 cells transiently transfected with full-length murine ADAM33 or green fluorescent protein (GFP) as control were treated with TGF-β as indicated. Soluble ADAM33 immunoreactivity and enzyme activity in cell-free supernatants were assessed by Western blotting (A) with densitometry (arbitrary units, AU) (B) or fluorescence resonance energy transfer peptide cleavage assay, respectively; enzyme activity is expressed as percent of activity found in supernatants from control untreated cells (C). Data are mean + SD and are representative of 4 independent experiments. MW, Molecular weight. **P < .01. ***P < .001.
Fig E2
Fig E2
The broad-spectrum MMP inhibitor GM6001 does not inhibit ADAM33 shedding. Cos-7 cells transiently transfected with full-length murine ADAM33 were preincubated with GM6001 (0-10 μM) for 1 hour before addition of 5 ng/mL TGF-β for 8 hours. Cell-free supernatants were assessed for soluble ADAM33 by Western blotting (A) with densitometry (arbitrary units, AU) (B) and by fluorescence resonance energy transfer peptide cleavage assay (C). Purified recombinant ADAM33 protein was incubated with GM6001 and tested for activity in a fluorescence resonance energy transfer peptide cleavage assay (D). Activity is presented as a percent of that measured in the absence of GM6001. MW, Molecular weight. Data are expressed as mean + SD and are representative of 4 independent experiments.
See this image and copyright information in PMC

References

    1. Lee J.Y., Park S.W., Chang H.K., Kim H.Y., Rhim T., Lee J.H. A disintegrin and metalloproteinase 33 protein in patients with asthma: relevance to airflow limitation. Am J Respir Crit Care Med. 2006;173:729–735. - PubMed
    1. Davies E.R., Kelly J.F., Howarth P.H., Wilson D.I., Holgate S.T., Davies D.E. Soluble ADAM33 initiates airway remodeling to promote susceptibility for allergic asthma in early life. JCI Insight. 2016;1 e87632. - PMC - PubMed
    1. Puxeddu I., Pang Y.Y., Harvey A., Haitchi H.M., Nicholas B., Yoshisue H. The soluble form of a disintegrin and metalloprotease 33 promotes angiogenesis: implications for airway remodeling in asthma. J Allergy Clin Immunol. 2008;121:1400–1406. 1406.e1-4. - PubMed
    1. Orth P., Reichert P., Wang W., Prosise W.W., Yarosh-Tomaine T., Hammond G. Crystal structure of the catalytic domain of human ADAM33. J Mol Biol. 2004;335:129–137. - PubMed
    1. Zou J., Zhu F., Liu J., Wang W., Zhang R., Garlisi C.G. Catalytic activity of human ADAM33. J Biol Chem. 2004;279:9818–9830. - PubMed

Publication types